Publications
13
Citations
64
Est. group size
—
Recurring co-author estimate
Active years
26
Publishing since 2001
Bradley Elder's work focuses on the surgical and clinical management of brain tumors, particularly high-grade gliomas and glioblastoma, including the use of gene therapy approaches like Toca 511/Toca FC and cytoreductive surgery. His publications also touch on neurosurgical leadership in clinical trials and evidence-based treatment guidelines for progressive glioblastoma. This research is relevant to students interested in neuro-oncology, neurosurgery, and translational cancer therapeutics.
Publication output was modest and fairly steady from 2017-2021, dropped to near zero in 2022-2023 and 2025, with a small resurgence in 2024 and 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- AMT-130 Huntington’s Disease Gene Therapy: Clinical Study Outcomes at Three Years (PL6.001)
Neurology · 2026
- Neurosurgical leadership in neuro-oncology clinical trials: A nationwide study
Neurosurgical Review · 2026
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults
Research Square · 2021
- Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma (S23.006)
Neurology · 2018
- Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
Molecular Cancer Therapeutics · 2018
- Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma (S23.006)
2018
- ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT
Neuro-Oncology · 2017
- ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL
Neuro-Oncology · 2016
- Neuro-Oncology×4
- Neurology×3
- Research Square×1
- Molecular Cancer Therapeutics×1
- Neurosurgery×1
- Susan D. Bell
Medicine · The Ohio State University
- Fernando M. Núñez
Medicine · The Ohio State University
- John R. Jacob
Medicine · The Ohio State University
- Kathryn Nevel
Medicine · Indiana University
- Diana Thomas
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile